Multispecific yet truly natural antibodies

Multispecific yet truly natural antibodies

Multispecific yet truly natural antibodies

Light Chain Bioscience brings to life the research and development of multi-specific antibodies that rely on their light chains for function
Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Read more
Our focus
Our focus

Multispecific yet natural

Multispecific yet natural

Read more
CD47 Dual targeting
CD47 Dual targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

Read more
Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

Read more
previous arrow
next arrow

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody

AACR Annual Meeting 2024 - Sara Majocchi -

New publication : Development and characterization of NILK-2301

A novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

7th Annual Immuno-Oncology Summit Europe 2023

Antibody Engineering & Therapeutics Europe- Sara Majocchi -

TM & © Novimmune SA. All rights reserved.
webdesign byhosted climate friendly

First patient dosed with NILK-2301 in Phase I clinical trial

Written by Mei Liang Belhumeur on . Posted in News

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer

Read more

LinkedIn